ReviewDrugs in context2020
Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib.
Review in Drugs in context, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 4 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Efficacy and safety of treatments for atopic dermatitis: a model based meta-analysis of randomized controlled trials.European journal of clinical pharmacology · 2026Pooled it
- Efficacy and safety of the JAK1 inhibitor abrocitinib for moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.Frontiers in immunology · 2024Pooled it
- Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Pooled it
- Efficacy of abrocitinib in patients with atopic dermatitis resistant to Janus kinase inhibitors.Skin health and disease · 2026Article
- Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications.Nature reviews. Drug discovery · 2026Review
- Pharmacologic Inhibition of JAK1/2 Potentiates Aminoglycoside-Induced Ototoxicity.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2026Article
- Extended treatment of abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis.Frontiers in medicine · 2026Article
- Efficacy and Safety of Abrocitinib in an Elderly Chinese Population with Moderate-to-Severe Atopic Dermatitis: A Non-randomized Controlled Trial.Acta dermato-venereologica · 2025Article
- Understanding Atopic Dermatitis: Pathophysiology and Management Strategies.Biomolecules · 2025Review
- Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics.Current issues in molecular biology · 2025Review
- Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study.Journal of clinical medicine · 2025Article
- Evaluation of Olive Oil-Based Formulations Loaded with Baricitinib for Topical Treatment of Alopecia Areata.Pharmaceutics · 2025Article
- Chronic Hand Eczema (CHE): A Narrative Review.Dermatology and therapy · 2025Review
- ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis.Immunotherapy · 2025Article
- Bioinformatics‑Based Analysis Reveals Diagnostic Biomarkers and Immune Landscape in Atopic Dermatitis.Clinical, cosmetic and investigational dermatology · 2025Article
- Overlapping features of atopic dermatitis and alopecia areata: from pathogenesis to treatment.Frontiers in immunology · 2025Review
- Innovative microbial strategies in atopic dermatitis.Frontiers in immunology · 2025Review
- Severe mixed hand and generalized eczema treated with the JAK inhibitor upadacitinib.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
- Herpes Zoster and Venous Thromboembolism Following Upadacitinib Treatment for Severe Atopic Dermatitis.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Janus kinases (JAK) are a group of molecules, composed of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), which are key components within the JAK-signal transducers and activators of transcription pathway, where cytokine receptor signaling takes place. These molecules play a foundational role in the underlying pathogenesis of multiple immune-related conditions such as atopic dermatitis (AD), rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and others. Thus far, JAK inhibitors for inflammatory conditions have only been marketed for the treatment of rheumatoid arthritis and psoriatic arthritis, but ongoing phase II and phase III clinical trials for other immune-mediated diseases, such as AD, have also shown promising results. This review summarizes the clinical data available from various trials and reports on the safety and efficacy of abrocitinib, baricitinib, and upadacitinib, the three oral systemic JAK inhibitors used in the treatment of AD. The safety and efficacy of JAK inhibitors for the treatment of AD are emerging in the literature. It is important that dermatologists are aware of any potential adverse events or risks associated with the use of JAK inhibitors in order to promote a higher standard of treatment and quality of living.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.